个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共12条记录   Bisphosphonates and Bone Diseases: Past, Present and Future [作者：Heymann, D,期刊：Current Pharmaceutical Design, 页码：2948-2949 , 文章类型： Editorial Material，,卷期：2010年16-27] Molecular Targets of the Nitrogen Containing Bisphosphonates: The Molecular Pharmacology of Prenyl Synthase Inhibition [作者：Dunford, JE,期刊：Current Pharmaceutical Design, 页码：2961-2969 , 文章类型： Review，,卷期：2010年16-27] The nitrogen containing bisphosphonates (N-BP) are the drug of choice for treating disease characterised by resorption of bone such as osteoporosis and metastatic bone disease. The overall mechanism of action is achieved... Assessment of Bishosphonate Activity In Vitro [作者：Mitrofan, LM; Auriola, S; Monkkonen, H; Monkkonen, J,期刊：Current Pharmaceutical Design, 页码：2970-2980 , 文章类型： Review，,卷期：2010年16-27] Bisphosphonates are a class of drugs developed over the past three decades for the treatment of metabolic bone diseases with high bone turnover, such as Paget's disease, tumor associated osteolysis and osteoporosis. The ... Combined Therapies of Bone Disease with Bisphosphonates [作者：Syddall, SP; Ottewell, PD; Holen, I,期刊：Current Pharmaceutical Design, 页码：2988-2997 , 文章类型： Review，,卷期：2010年16-27] Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is... Prevention and Treatment of Bone Metastases [作者：Woodward, EJ; Coleman, RE,期刊：Current Pharmaceutical Design, 页码：2998-3006 , 文章类型： Review，,卷期：2010年16-27] Certain primary tumours including breast and prostate cancers have a particular propensity for metastasis to bone. Metastatic bone disease can have significant impact on morbidity and mortality of cancer patients. Skelet... Therapeutic Approach of Primary Bone Tumours by Bisphosphonates [作者：Moriceau, G; Ory, B; Gobin, B; Verrecchia, F; Gouin, F; Blanchard, F; Redini, F; Heymann, D,期刊：Current Pharmaceutical Design, 页码：2981-2987 , 文章类型： Review，,卷期：2010年16-27] Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas. ii) and giant cell tumour and bone metastases originate from others ... Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates [作者：Buijs, JT; Kuijpers, CCHJ; van der Pluijm, G,期刊：Current Pharmaceutical Design, 页码：3015-3027 , 文章类型： Review，,卷期：2010年16-27] Cancer is a major leading cause of death in the western world (following heart diseases). It poses an enormous burden on patients and society with a major impact on healthcare and economy. Once cancers have spread to the... Bisphosphonate Therapy in the Treatment of Multiple Myeloma [作者：Lawson, MA; Ashcroft, J; Croucher, PI,期刊：Current Pharmaceutical Design, 页码：3028-3036 , 文章类型： Review，,卷期：2010年16-27] Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been ... Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy [作者：Clezardin, P; Massaia, M,期刊：Current Pharmaceutical Design, 页码：3007-3014 , 文章类型： Review，,卷期：2010年16-27] Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone... Alternative Use of Bisphosphonate Therapy for Rheumatic Disease [作者：Le Goff, B; Berthelot, JM; Maugars, Y; Romas, E,期刊：Current Pharmaceutical Design, 页码：3045-3052 , 文章类型： Review，,卷期：2010年16-27] Bisphosphonates are widely use for pathologies such as osteoporosis, Paget's disease or bone metastasis. However, their potent antiresorptive properties open new therapeutic opportunities for other conditions associated ... A Comparison Between Bisphosphonates and Other Treatments for Osteoporosis [作者：Le Goff, B; Guillot, P; Glemarec, J; Berthelot, JM; Maugars, Y,期刊：Current Pharmaceutical Design, 页码：3037-3044 , 文章类型： Review，,卷期：2010年16-27] Since their development 30 years ago, bisphosphonates are now one of the standard therapy in the management of osteoporosis. Improvements in terms of anti-resorptive potency have leaded to new molecules available either ... Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages [作者：Roelofs, AJ; Thompson, K; Ebetino, FH; Rogers, MJ; Coxon, FP,期刊：Current Pharmaceutical Design, 页码：2950-2960 , 文章类型： Review，,卷期：2010年16-27] Bisphosphonates are widely used in the treatment of diseases involving excessive bone resorption, such as osteoporosis, cancer-associated bone disease, and Paget's disease of bone. They target to the skeleton due to thei...